ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
Biotechnology-Research
Website
Industry Category
Business Keywords
Company Description
ImClone Systems, a subsidiary of Eli Lilly and Company, is a biopharmaceutical company dedicated to advancing oncology care. ImClone Systems develops and commercializes targeted biologic treatments aimed at addressing the unmet medical needs of patients with various cancers. With a strong focus on innovation and patient outcomes, ImClone Systems is committed to making a significant impact in the field of oncology.
ImClone Systems operates as a fully integrated global entity, ensuring that its research and development efforts translate into effective and accessible treatments. By focusing on targeted biologic therapies, ImClone Systems strives to improve the quality of life for cancer patients worldwide. The company's work reflects a deep understanding of the complexities of cancer and a dedication to finding innovative solutions.
ImClone Systems continues to build on its legacy of pioneering advancements in cancer treatment, contributing to the overall progress of the biopharmaceutical industry. We invite the manager of ImClone Systems to create a customized and exclusive company showcase and product listing on our platform to further highlight their contributions.
Key Personnel / Employees
Similar Companies
Other organizations in the same industry
ADMA Biologics, Inc.
Biotechnology-ResearchHiring at our Boca Raton, FL campus!
Juvena Therapeutics
Biotechnology-ResearchDecoding Secreted Proteins
DIA.PRO Diagnostic Bioprobes S.r.l.
Biotechnology-ResearchAn italian company dedicated to providing innovative & cost effective in-vitro diagnostic products
Alternative Company Names
This company is also known as